NumFin

Guizhou Xinbang Pharmaceutical Co., Ltd.

Sümbol: 002390.SZ

SHZ

3.89

CNY

Turuhind täna

  • 32.8887

    P/E suhe

  • -2.3022

    PEG suhe

  • 7.06B

    MRK Cap

  • 0.01%

    DIV tootlus

Guizhou Xinbang Pharmaceutical Co., Ltd. (002390-SZ) Finantsaruanded

Download
AastaneQuarterly
LineaarneLog
Diagrammil näete Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) vaikimisi numbreid dünaamikates. Companys revenue näitab keskmist NaN M, mis on NaN % gowth. Kogu perioodi keskmine brutokasum on NaN M, mis on NaN %. Keskmine brutokasumi suhtarv on NaN %. Ettevõtte eelmise aasta tulemuse puhaskasv on NaN %, mis on võrdne NaN % % keskmiselt kogu ettevõtte ajaloo jooksul.,

AastaneQuarterly
10Y20Y30Y40Y

Bilanss

Sukeldudes Guizhou Xinbang Pharmaceutical Co., Ltd. fiskaalkäiguteele, täheldame keskmist varade kasvu. See määr on huvitaval kombel , mis kajastab nii ettevõtte kõrg- kui ka madalseisusid. Kui võrrelda kvartalite lõikes, siis kohandub see näitaja . Kui vaadata tagasi möödunud aastale, siis on varade kogumuutus NaN. Aktsionäride väärtus, mida näitab aktsionäride kogu omakapital, on hinnatud NaN aruandlusvaluutas. Selle aspekti aastane muutus on NaN%.

common:word.in-mln

USD
Growth
TTM20222021202020192018201720162015201420132012201120102009200820072006

balance-sheet.row.cash-and-short-term-investments

0899.2624.61776.4
1235.6
1614.2
2145.1
1674.3
603.1
659
254.4
360.1
513.3
629.2
83.4
71.1
39.9
62.4

balance-sheet.row.short-term-investments

0000
0
-132.2
-89.7
-34.9
-30.9
-5
0
0
0
0
0
0
0
0

balance-sheet.row.net-receivables

03870.64011.33466.8
3932.9
3996.8
3405.7
3066.6
2548.9
2020.8
393.4
390.3
322.9
239.7
174.7
175
189.8
160.1

balance-sheet.row.inventory

01032.7935.7843.4
994.3
1044.5
700
744.4
614.9
544.6
326.5
175.7
142.3
71.6
66.1
62.1
34.5
33.6

balance-sheet.row.other-current-assets

03.74.74.6
12.6
17.9
87
156.1
60.6
100
80
20
-33
-23.7
0
-16.8
-23.7
-24.9

balance-sheet.row.total-current-assets

05806.25576.46091.1
6175.5
6673.4
6337.8
5641.5
3827.4
3324.4
1054.3
946.1
945.5
916.9
324.1
291.5
240.4
231.2

balance-sheet.row.property-plant-equipment-net

02671.72705.92323.2
2750.5
2774.6
2707.4
2360.2
1754.8
866.5
334.6
313.9
273.7
192.1
133
140.7
139.8
144.2

balance-sheet.row.goodwill

0607.3607.3605.5
778.2
778.2
2319
2319
647.6
647.6
38.1
38.1
0
0
0
0
0
0

balance-sheet.row.intangible-assets

0204.4217.6219.6
307.8
328
336.6
348.5
166
144.4
30.6
24.3
12.5
11.1
11.7
9.4
9.9
2.7

balance-sheet.row.goodwill-and-intangible-assets

0811.7825825.1
1086
1106.3
2655.6
2667.5
813.6
792
68.7
62.4
12.5
11.1
11.7
9.4
9.9
2.7

balance-sheet.row.long-term-investments

0343.8347.4223
146.3
220.7
182.6
64.9
60.9
15
0
0
0
0
0
0
0
0

balance-sheet.row.tax-assets

062.455.646.5
52.9
43.3
35.5
27
12.2
9.4
2.3
2.2
1.8
1.4
1.5
1.1
1
1.1

balance-sheet.row.other-non-current-assets

097.2118.4153.2
208.2
36
36
36
36
216
26.7
10.1
10.1
4
0
0
0
0.1

balance-sheet.row.total-non-current-assets

03986.94052.33571
4243.9
4180.9
5617.1
5155.6
2677.5
1898.9
432.3
388.5
298.1
208.7
146.2
151.3
150.6
148.1

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

09793.19628.69662.2
10419.4
10854.3
11955
10797.1
6504.9
5223.3
1486.6
1334.6
1243.6
1125.5
470.3
442.7
391.1
379.3

balance-sheet.row.account-payables

0977.2993.4788.6
1020.9
1060.4
1198.4
1195.6
1143
736.8
64.9
37.5
45.7
12.7
12.8
8
12.6
3.3

balance-sheet.row.short-term-debt

01345.81362.33382.5
3460.4
3876.2
3392.4
2791.6
2340.9
1807.5
321.9
235.1
194.9
134.9
173.9
195.9
155.9
179.9

balance-sheet.row.tax-payables

033.337.432.2
44.1
35.9
45.1
53.5
46.9
20.3
3.7
4.6
1.5
1.7
12
7.7
3.7
1.9

balance-sheet.row.long-term-debt-total

02224.824.5
298.6
323.2
297.8
0
16.5
13.5
0
0
0
0
0
0
22.1
22.1

Deferred Revenue Non Current

018.920.422.9
62.6
24.9
24
27.8
47
42.8
23.8
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

0330.66.54.6
99.6
364.8
33.9
46.7
44.2
48.2
2.3
2.5
3
6
5.2
5
1.7
2.2

balance-sheet.row.total-non-current-liabilities

041.245.523.2
361.6
348.5
322.2
28.2
64
56.8
23.8
20.7
10.9
0
3.5
6
29.1
29.3

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

02224.824.5
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

027282800.14493.7
5371.1
5685.8
5196.3
4312.1
3835.9
2765.4
450.7
312
264
165.8
217.5
235
217
235.2

balance-sheet.row.preferred-stock

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

01943.92027.21667.2
1667.2
1667.2
1704.9
1704.9
1251.1
500.5
173.6
173.6
173.6
86.8
65.1
65.1
65.1
65.1

balance-sheet.row.retained-earnings

0373.2271.528
-126.7
-363
964.8
699.2
506.6
366.7
242.1
215.9
183.6
168.3
134.5
92.8
62.5
35.6

balance-sheet.row.accumulated-other-comprehensive-income-loss

0189.6102.757.3
63.3
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-total-stockholders-equity

04301.74218.43165.9
3233.2
3663.2
3945.7
3948
784.2
1529.8
619.3
628.1
623.1
705.1
53.6
48.6
45.1
42.1

balance-sheet.row.total-stockholders-equity

06808.56619.84918.3
4837.1
4967.5
6615.3
6352.1
2541.9
2396.9
1034.9
1017.7
980.3
960.2
253.2
206.5
172.6
142.8

balance-sheet.row.total-liabilities-and-stockholders-equity

09793.19628.69662.2
10419.4
10854.3
11955
10797.1
6504.9
5223.3
1486.6
1334.6
1243.6
1125.5
470.3
442.7
391.1
379.3

balance-sheet.row.minority-interest

0256.6208.7250.2
211.2
201.1
143.3
132.9
127.1
61
1
5
-0.7
-0.5
-0.3
1.2
1.4
1.4

balance-sheet.row.total-equity

070656828.55168.5
5048.3
5168.5
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

0343.8347.4223
146.3
88.4
92.9
30.1
30.1
10.1
26.4
10.1
10.1
4
0
0
0
0

balance-sheet.row.total-debt

01367.81387.13382.5
3759
4199.4
3690.1
2791.6
2357.4
1807.5
321.9
235.1
194.9
134.9
173.9
195.9
177.9
201.9

balance-sheet.row.net-debt

0468.6762.51606.1
2523.4
2585.1
1545
1117.2
1754.2
1148.4
67.5
-125
-318.5
-494.3
90.6
124.8
138.1
139.5

Rahavoogude aruanne

Guizhou Xinbang Pharmaceutical Co., Ltd. finantsmaastikul on viimase perioodi jooksul toimunud märkimisväärne muutus vabas rahavoos, mis näitab NaN nihet. Ettevõte laiendas hiljuti oma aktsiakapitali, emiteerides NaN, mis tähistab NaN erinevust võrreldes eelmise aastaga. Ettevõtte investeerimistegevuse tulemusel kasutas ettevõte netosularaha, mis aruandlusvaluutas oli NaN. See on NaN nihkumine võrreldes eelmise aastaga. Samal perioodil registreeris ettevõte NaN, NaN, NaN, mis on olulised ettevõtte investeerimis-ja tagasimaksestrateegiate mõistmiseks. Ettevõtte finantseerimistegevuse tulemusel kasutas ettevõte netorahavahendeid NaN, kusjuures erinevus võrreldes eelmise aastaga oli NaN. Lisaks eraldas ettevõte NaN aktsionäridele dividendide maksmiseks. Samal ajal tegi ta muid finantsmanöövreid, millele viidatakse kui NaN, mis samuti mõjutasid oluliselt tema rahavooge sel perioodil. Need komponendid koos annavad tervikliku pildi ettevõtte finantsseisundist ja strateegilisest lähenemisest rahavoogude juhtimisele.

common:word.in-mln

USD
Growth
TTM20222021202020192018201720162015201420132012201120102009200820072006

cash-flows.row.net-income

0268.4374220.6
263.7
-1283.2
331.5
242.7
168.4
153.9
39.7
47.6
45.9
37.6
46.4
33.6
29.9
17.5

cash-flows.row.depreciation-and-amortization

0243.5247.3231.6
238.4
214.9
174.6
150
126.7
50.1
19.7
7.6
6.8
7.4
7.6
7.6
6.9
0

cash-flows.row.deferred-income-tax

0-6.8-9.16.4
-9.6
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

031.56-6.4
9.6
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

0-117.1-338.674.8
151.7
-897.5
-435.1
-802.6
-217.2
-483.5
-98.5
-104.9
-102.7
-46.5
-21.8
-25.5
-13.9
0

cash-flows.row.account-receivables

095-609.8348.1
198.4
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

0-97-92.3150.9
50.1
-344.4
44.4
-90.1
-70.3
-79.8
-150.8
-29.9
-70.6
-5.6
-11.9
-27.6
-0.6
0

cash-flows.row.account-payables

0-108.3372.6-430.6
-87.2
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

0-6.8-9.16.4
-9.6
-553.1
-479.5
-712.5
-147
-403.6
52.3
-75
-32.1
-41
-9.9
2.2
-13.3
0

cash-flows.row.other-non-cash-items

0171.3178.4215
232.5
1747.3
130.7
211.3
139.6
80.9
17.8
13.4
10.1
4
9.5
9.1
9.6
-17.5

cash-flows.row.net-cash-provided-by-operating-activities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

0-158.8-253.8-138.1
-207.5
-263.5
-435
-432.2
-492.5
-282.6
-44.8
-52.8
-96.5
-74.6
-6.6
-7
-28.9
-39.3

cash-flows.row.acquisitions-net

01.6-295.5566.1
7.1
-39.1
-0.2
61.5
43.7
50.4
-34.3
-55.9
0
0
3.5
0
0
39.3

cash-flows.row.purchases-of-investments

0-12.4-1719.6-1516.5
-60
0
-439.8
-664
-211.1
-371.9
-426.5
-90
-6
-4
0
0
0
-3.4

cash-flows.row.sales-maturities-of-investments

0511523.61494.7
1.6
86.1
433.7
426.6
206.8
285.5
368.7
70.6
0
0
0
0
0
0.3

cash-flows.row.other-investing-activites

00.50.91.7
5.5
0.2
1.1
7.8
1.2
-54.4
0
0
0
0
0
5
6.6
-39.3

cash-flows.row.net-cash-used-for-investing-activites

0-118-744.3408
-253.3
-216.3
-440.2
-600.3
-451.9
-373.1
-136.9
-128.1
-102.5
-78.6
-3.2
-2
-22.3
-42.4

cash-flows.row.debt-repayment

0-2019.5-4257-3561.4
-4545.7
-3808.2
-2999.1
-2635.8
-2070.4
-914.3
-260.9
-197.1
-161.9
-151.9
-201.9
-175.9
-186.9
-127.9

cash-flows.row.common-stock-issued

00086.2
369.2
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.common-stock-repurchased

000-86.2
-369.2
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

0-168.4-230.3-197.6
-206.9
-252.5
-185.9
-179.6
-154.7
-89.1
-26.2
-21.4
-33.5
-3.5
-6.4
-9.6
-8.7
-11

cash-flows.row.other-financing-activites

01998.43576.73171.8
3769.9
3963.7
3867.9
4638.2
2396.8
1930.5
339.7
229.9
221.9
777.3
181.9
193.9
162.9
179.9

cash-flows.row.net-cash-used-provided-by-financing-activities

0-189.4-910.6-587.2
-982.8
-97
683
1822.9
171.7
927.1
52.5
11.4
26.5
622
-26.4
8.4
-32.7
41

cash-flows.row.effect-of-forex-changes-on-cash

0002.3
0.3
12.7
-10
8.5
0
0
0
0
0
0
0
0
0
0

cash-flows.row.net-change-in-cash

0283.4-1196.9565.2
-349.5
-519.1
434.5
1032.5
-62.7
355.4
-105.7
-153.2
-115.9
545.8
12.2
31.3
-22.6
5.9

cash-flows.row.cash-at-end-of-period

0797513.71710.6
1145.4
1494.9
2014
1579.5
547
609.8
254.4
360.1
513.3
629.2
83.4
71.1
39.9
62.4

cash-flows.row.cash-at-beginning-of-period

0513.71710.61145.4
1494.9
2014
1579.5
547
609.8
254.4
360.1
513.3
629.2
83.4
71.1
39.9
62.4
56.5

cash-flows.row.operating-cash-flow

0590.8458742.1
886.3
-218.6
201.7
-198.6
217.4
-198.6
-21.3
-36.5
-39.9
2.5
41.8
24.9
32.5
0

cash-flows.row.capital-expenditure

0-158.8-253.8-138.1
-207.5
-263.5
-435
-432.2
-492.5
-282.6
-44.8
-52.8
-96.5
-74.6
-6.6
-7
-28.9
-39.3

cash-flows.row.free-cash-flow

0432204.2604
678.8
-482.1
-233.3
-630.8
-275.1
-481.2
-66.1
-89.2
-136.3
-72.1
35.1
17.9
3.5
-39.3

Kasumiaruande rida

Guizhou Xinbang Pharmaceutical Co., Ltd. tulud muutusid võrreldes eelmise perioodiga NaN%. 002390.SZ brutokasum on teatatud NaN. Ettevõtte tegevuskulud on NaN, mille muutus võrreldes eelmise aastaga on NaN%. Kulud amortisatsioonikulud on NaN, mis on NaN% muutus võrreldes eelmise aruandeperioodiga. Tegevuskulud on teatatud NaN, mis näitab NaN% muutust võrreldes eelmise aastaga. Müügi- ja turunduskulud on NaN, mis on NaN% muutus võrreldes eelmise aastaga. Hiljutistel numbritel põhinev EBITDA on NaN, mis tähendab NaN% kasvu võrreldes eelmise aastaga. Tegevustulu on NaN, mis näitab NaN% muutust võrreldes eelmise aastaga. Puhaskasumi muutus on NaN%. Eelmise aasta puhaskasum oli NaN.

common:word.in-mln

USD
Growth
TTM20222021202020192018201720162015201420132012201120102009200820072006

income-statement-row.row.total-revenue

063506471.95845.6
6655.1
6580.3
6002.5
5157
4179.8
2476.2
569.5
447.6
361.9
318.6
336.7
274.7
217.8
173.3

income-statement-row.row.cost-of-revenue

05133.15119.44593.5
5190.5
5146.7
4745.9
4048.8
3318.6
1837.9
213.9
167
128.7
111.2
103.4
85.4
76.6
60.7

income-statement-row.row.gross-profit

012171352.51252.1
1464.5
1433.5
1256.6
1108.2
861.1
638.3
355.6
280.6
233.2
207.4
233.3
189.4
141.1
112.6

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

0292297.8268.3
325.4
-16
-3.3
84.5
44.1
24.2
10.3
11.6
-3.4
4.2
0.9
5.7
6.3
0.3

income-statement-row.row.operating-expenses

0836.4787.1802.1
943.7
929.1
730.4
712.2
555.4
397.5
307.8
232.4
190.5
169
170.9
147.6
103.6
85.8

income-statement-row.row.cost-and-expenses

05969.55906.55395.7
6134.3
6075.9
5476.3
4761.1
3874.1
2235.3
521.7
399.4
319.2
280.2
274.3
232.9
180.3
146.5

income-statement-row.row.interest-income

013.51415.4
17.1
16.3
24.1
29
16.3
10.1
6.1
11.1
15.9
4.6
0.3
0.4
0
0

income-statement-row.row.interest-expense

051.8100.299.6
164.8
149.8
105.8
129.6
125.2
74.1
16.6
11.8
7.5
3.5
6.5
9.5
9.2
4.3

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

0-114.4-30.4-162.5
-195.1
-1715.8
-107.1
-84
-77.5
-41.8
0
9.2
10.8
5.7
-8.2
-3.2
-3.1
-5.4

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

0292297.8268.3
325.4
-16
-3.3
84.5
44.1
24.2
10.3
11.6
-3.4
4.2
0.9
5.7
6.3
0.3

income-statement-row.row.total-operating-expenses

0-114.4-30.4-162.5
-195.1
-1715.8
-107.1
-84
-77.5
-41.8
0
9.2
10.8
5.7
-8.2
-3.2
-3.1
-5.4

income-statement-row.row.interest-expense

051.8100.299.6
164.8
149.8
105.8
129.6
125.2
74.1
16.6
11.8
7.5
3.5
6.5
9.5
9.2
4.3

income-statement-row.row.depreciation-and-amortization

0243.5347.7231.6
238.4
214.9
174.6
150
126.7
50.1
19.7
7.6
6.8
7.4
7.6
7.6
6.9
7.2

income-statement-row.row.ebitda-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

0427.8451.5429.9
526.6
-1195.4
422.4
231.2
184.4
175.1
37.5
45.9
48.6
38.9
53.3
32.9
28.1
21.2

income-statement-row.row.income-before-tax

0313.4421.1267.5
331.5
-1211.4
419.1
312
228.2
199
47.8
57.4
53.5
44.1
54.2
38.6
34.4
21.5

income-statement-row.row.income-tax-expense

04547.246.9
67.8
71.8
87.6
69.3
59.8
45.2
8.1
9.8
7.7
6.6
7.8
5
4.5
4.6

income-statement-row.row.net-income

0224.5374173.5
236.3
-1296.6
319.4
246
174.4
144.8
40.2
47.8
46.1
37.8
46.4
33.6
29.9
17.5
Sarnased aktsiad
Sind võib huvitada ka:
CHSYF
China Medical System Holdings Limited.
0.9313 USD
PNK
600479.SS
ZhuZhou QianJin Pharmaceutical Co.,Ltd.
10.92 CNY
SHH
WOCKPHARMA.BO
Wockhardt Limited.
532.5 INR
BSE
185750.KS
Chong Kun Dang Pharmaceutical Corp..
100300 KRW
KSC
ERIS.NS
Eris Lifesciences Limited.
848.1 INR
NSE
300601.SZ
Shenzhen Kangtai Biological Products Co., Ltd..
22.39 CNY
SHZ
TKPHF
Takeda Pharmaceutical Company Limited.
26.83 USD
PNK
MVP.AX
Medical Developments International Limited.
0.61 AUD
ASX
APLLTD.NS
Alembic Pharmaceuticals Limited.
1001.35 INR
NSE
128940.KS
Hanmi Pharm. Co., Ltd..
321500 KRW
KSC
002390.KS
HANDOK Inc..
13700 KRW
KSC

Korduma kippuv küsimus

Mis on Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) koguvara?

Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) koguvara on 9793091573.000.

Mis on ettevõtte aastane tulu?

Aastane tulu on N/A.

Mis on ettevõtte kasumimarginaal?

Ettevõtte kasumimarginaal on 0.190.

Mis on ettevõtte vaba rahavoog?

Vaba rahavoog on 0.334.

Mis on ettevõtte puhaskasumimarginaal?

Puhaskasumimarginaal on 0.037.

Mis on ettevõtte kogutulu?

Kogutulu on 0.053.

Mis on Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) puhaskasum (puhaskasum)?

Puhaskasum (netotulu) on 224479086.000.

Kui suur on ettevõtte koguvõlg?

Koguvõlg on 1367777175.000.

Mis on tegevuskulude arv?

Tegevuskulud on 836448131.000.

Milline on ettevõtte rahaline näitaja?

Ettevõtte raha on 0.000.